Suboptimal use of hormonal therapy among German men with localized high-risk prostate Cancer during 2005 to 2015: analysis of registry data

Background This study assesses the use of hormonal therapy to treat high-risk localized prostate cancer (HRLPCa) cases diagnosed between 2005 and 2015. Methods All N 0-X M 0 with ≥T 3a, or PCa cases with poorly differentiated feature (equivalent to Gleason score ≥ 8), diagnosed between 2005 and 2015...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	BMC cancer Ročník 22; číslo 1; s. 624 - 13
Hlavní autori:	Abera, Semaw Ferede, Bedir, Ahmed, Glowka, André, Vordermark, Dirk, Medenwald, Daniel
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 07.06.2022 BioMed Central Ltd Springer Nature B.V BMC
Predmet:	Androgen Antagonists - therapeutic use Antineoplastic Agents, Hormonal - therapeutic use Biomedical and Life Sciences Biomedicine Cancer registry Cancer Research Cancer therapies Care and treatment Chemotherapy Health Promotion and Disease Prevention High-risk Hormonal therapy Hormone therapy Humans Life expectancy Male Medicine/Public Health Mortality Neoplasm Grading Oncology Patients Population Prostate Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - radiotherapy Radiation therapy Registries Research Article S3-guideline Statistics Surgery Surgical Oncology Treatment Germany Treatment Cancer registry S3-guideline Prostate cancer High-risk Germany Hormonal therapy
ISSN:	1471-2407, 1471-2407
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!